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The Italian Societies of Hematology and Blood Transfu-
sion issued recent recommendations for phlebotomy in
polycythemia vera (PV), to obtain a target hematocrit
<45% [1]. Selective red blood cell (RBC) apheresis
(erythrocytapheresis, ECP) is recommended as an alter-
native to phlebotomy only when a rapid attainment of the
target hematocrit is needed, such as occurrence of severe
vascular complications, or before emergency surgery [1].
We suggest an additional indication, offering ECP to
those patients who require numerous rounds of phle-
botomy, and have contraindications or unwillingness to
use cytoreductive therapy. Here we report an emblematic
case of a PV patient diagnosed at the age of 39 years; her
main symptom was severe acromelalgia. From 2001 to
2016, she received low-dose aspirin and a median number
of 7 phlebotomies/year (range 5–8), on average every
47 days (range 22–124). Over this time, she recurrently
expressed her discomfort with the high phlebotomy
requirement, but she was extremely concerned to start
interferon or hydroxycarbamide. In September 2016, ECP
was implemented in an attempt to reduce the phlebotomy
rate. Figure 1 compares the findings of the ECP period
(September 2016–August 2018) to those of the previous 3
years with phlebotomies (September 2013–August 2016).
No signs of myelofibrotic evolution were present. The
median RBCs removed were 165 ml (range 134–188)
after phlebotomies and 259 ml (range 256–266) after
ECP. ECP resulted in a straighter hematocrit control; the
frequency of procedures gradually lowered, with a med-
ian interval between ECP of 58 days (range 28–152), and
acromelalgia completely disappeared (Fig. 1). No adverse
reaction occurred. Overall, this case suggests that ECP
may be attempted if phlebotomy fails to control hema-
tocrit and/or PV-related symptoms.
Isovolemic ECP removes a large RBC volume without
affecting donor blood volume, tailoring the withdrawal to
both pre-procedure and target hematocrit. However, the use
in PV patients has been scarcely explored [2–4]. ECP and
phlebotomy were employed in 30 and 99 PV patients,
respectively, during a period of 3.5 years. In comparison
with phlebotomies, ECP removed more RBC volume and
lowered hematocrit better, requiring half-procedures [4].
The interval between procedures is reported to be
longer after ECP: 20 days–4 months after phlebotomy and
4–7 months after ECP [2–4]. The major efficacy of ECP
over phlebotomy has been confirmed in two randomized
trials in patients with hemochromatosis [5, 6].
The main concerns against the routine management of
PV patients by ECP are apheresis-related adverse events
and the high cost [1]. In two series of 62 and 40 patients
with erythrocytosis, the rate of ECP-related adverse
events was <2% [3] and up to 32.5% [4], respectively. All
events were attributable to the hypocalcemia caused by
citrate in the ACD-A anticoagulant, but were mild and
without need of calcium supplementation [4]. Indeed,
mild citrate-induced symptoms (perioral tingling,
malaise, nausea, and chills) occur in up to 80% of healthy
apheresis donors. Severe symptoms (convulsions and
laryngeal spasm) occur up to 0.4% of procedures [7], with
a rate comparable with the 0.1–0.5% rate of severe
adverse vasovagal reactions recorded during whole blood
donations [7].
ECP is about 3.5-fold more expensive than phlebotomy,
either due to the higher cost of devices or because of the
indirect costs due to the longer time employed by specia-
lized personnel [3, 5, 6]; the difference in the total costs is
only partially mitigated by the longer interval after ECP
[5, 6]. However, among hemochromatosis patients, ECP
results in less hours of absence from work and less costs of
lost production, with an overall cost per procedure lower by
one-third in comparison with phlebotomy [5].
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Up to 25% of PV patients perceive phlebotomies as
having a negative impact on quality of life (QOL) and
productivity, and up to 8% of patients discontinue phlebo-
tomies because they feel worse after treatment, or for the
inconvenient frequency of visits [8]; in this regard, lowering
the frequency of procedures, likewise maintaining a control
of hematocrit and of symptoms, is an important clinical
need.
A randomized trial in PV patients managed by RBC
withdrawal could be appropriate, investigating the different
effects of ECP and phlebotomy on target hematocrit, fre-
quency of procedures, disease-associated symptoms, vas-
cular complications, working activity, and QOL, as well as
iron deprivation and its clinical consequences [9]. The cost–
efficacy analysis of ECP should consider all these
outcomes.
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